She obtained her PharmD degree (2006) and her PhD degree (2011) in Biomedical and Pharmaceutical sciences at ULB. She is now Lecturer at ULB and develops the research projects in inhalation field (pulmonary and nose-to-brain). She had supervised/is supervising 15 PhD students until now.
She has published more than 50 peer-reviewed papers in internationally recognized journals, more than 50 abstracts and conference proceedings and is co-inventor on 5 patents. She is also co-founder of the InhaTarget Therapeutics, a spin-off company of the ULB.
Her research focuses on the DPI development to combat different diseases (e.g. lung tumors, infectious diseases, and asthma), and that with different dose (µg to tens of mg) and kind of drugs (e.g. poorly or freely water soluble - conventional or from biotechnologies), with optimal aerodynamic performance, lung retention and eventually increased cell or tumor penetration. Therefore, the formulations were evaluated in vitro on culture cells and in vivo on preclinical models.
Nasal formulations for the nose to brain delivery of nucleic acids or peptide were also developed and evaluated in vitro on epithelial cell membrane and in vivo by histology and on preclinical models.